Introduction

The UK’s CBD landscape is on the cusp of a notable shift. In September 2025 the Food Standards Agency opened a consultation on approving the first CBD food products as Novel Foods in Great Britain, signalling that edible CBD — notably microdosed gummies — may soon have a clearer regulatory route. For brands, retailers and consumers this is an inflection point: opportunities for mainstream edible launches are growing even as expectations around safety, transparency and responsible labelling tighten.

Why the Novel Food consultation matters

The FSA’s September 2025 consultation considers approving specific CBD food products as Novel Foods and includes proposals for mandatory safety warnings on ingestible CBD. While approvals remain in progress, the consultation itself is important because it sets out potential conditions and labelling expectations that will shape how edible CBD products are launched, marketed and sold in Great Britain.

Regulatory context without medical promises

It’s important to stress that Novel Food approval is a safety and regulatory step, not an endorsement that CBD is a medicine. Under UK advertising guidance, brands must avoid medical claims. Instead, many brands will position edibles in wellness terms — for example, saying products "may support a sense of calm" or that "some users report improved routine wellbeing."

Market momentum and consumer demand

The commercial backdrop helps explain why so many companies are watching the FSA process closely. The UK CBD market reached approximately USD 997.4 million in 2025 and is forecast to grow to roughly USD 2.56 billion by 2034 (IMARC Group), implying a double‑digit compound annual growth rate in the coming decade. Retail and editorial coverage during 2025–26 has repeatedly highlighted strong consumer appetite for CBD edibles, especially microdosed gummies and flavour-forward gummy ranges that mainstream retailers are beginning to stock.

What consumers are seeking

• Lower-dose formats that fit everyday routines — microdoses in the 2.5–5mg range are increasingly requested.
• Clear, trustworthy labelling and third‑party certificates of analysis (COAs).
• Flavourful, well‑formulated options that feel like a food or treat rather than a medicinal product.

Product innovation accelerating

Innovation is happening fast. Brands are pairing CBD with adaptogens, launching water‑soluble formats for faster onset and higher‑bioavailability transdermal options. In 2025 pharmacy‑grade CBD patches and other transdermal products began to appear, reflecting a diversification away from oils alone. Non‑ingestible categories such as topicals and cosmetics have faced fewer regulatory obstacles and continue to scale as a lower‑risk revenue channel while ingestible approvals progress.

Wylde’s edible and ingestible portfolio illustrates the breadth of options consumers encounter: from gummy ranges to tinctures and drink enhancers. Examples include Wylde CBD gummy bears in smaller jars and larger packs (30x 10mg, 60x 10mg), as well as water‑friendly formats like the CBD drinks enhancer and alternative edible options such as CBD Living gummies and CBD Living sour gummies.

What brands need to prepare

For brands planning edible launches, the near‑term priorities are clear:

• Design with compliance in mind: anticipate mandatory safety warnings and design packaging to accommodate them without clutter. Keep language focused on wellness — avoid therapeutic claims.
• Precise microdose labelling: consumers searching for "best CBD gummies 2026" increasingly want clear potency labels and per‑serving dosages. If you’re offering microdosed gummies, list CBD per piece and per serving plainly.
• Robust testing and provenance: third‑party COAs must be easy to access. Many brands now include QR codes on packs that link to batch‑specific lab reports.
• Adopt new trust tools: industry platforms launched in 2025 use AI to present batch lab reports more clearly and flag anomalies — adopting these tools can reassure retailers and consumers.
• Formulation and shelf stability: water‑soluble and gummy matrices require careful formulation to ensure consistent dosing and long shelf life; invest in stability testing.

What consumers should look for

If you’re considering CBD edibles, particularly microdosed options, here are practical checks to make:

• Third‑party COAs: look for batch‑specific certificates that show CBD and THC content and contaminant screening.
• Clear microdose information: each gummy should show CBD per piece and the number of servings per pack.
• Transparent ingredients: check for additional actives such as adaptogens or melatonin and ensure they’re listed with quantities.
• Trusted retailers and brands: mainstream retail availability often correlates with higher compliance scrutiny; you might explore reputable options like Cannacoffee ground, whole‑bean or convenient pods for non‑gummy ways to sample CBD.

Looking ahead: an emerging mainstream category

As Novel Food approvals evolve, the interplay between regulation, retail demand and technical innovation will define the shape of the edible market. The likely outcome is a more standardised, transparent offer of microdosed gummies and flavour-led edibles that fit everyday routines — supported by clear labelling, third‑party testing and digital trust tools. In the meantime, topical and cosmetic CBD categories continue to provide a lower‑regulatory‑risk revenue stream for brands while edible approvals are finalised.

Conclusion

The FSA consultation opened in September 2025 is a milestone on the road to regulated CBD edibles in Great Britain. For brands, it means planning product launches with compliance, transparency and consumer expectations at the centre; for consumers, it means greater choice and higher standards when microdosed gummies finally scale. Whether you explore flavour‑forward gummies, water‑soluble formats or classic tinctures and lozenges — examples of which include CBD Living lozenges, CBD Living PM syrup and Wylde natural cold‑pressed drops in several strengths (1000mg, 2000mg, 4000mg), the underlying rules will be the same: clear labelling, verified testing and responsible marketing.

As the sector matures, consumers and brands who prioritise transparency and quality will find the most reliable path to trust — and to a mainstream edible market that feels safe, sophisticated and accessible.

For further reading: explore microdose options like Wylde gummy bears and water‑soluble enhancers, and seek out products that share batch COAs before purchase.